2023-507874-42-00招募中2 期
A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Bruno STANKOFF
Scientific
Assistance Publique Hopitaux De Paris
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MSMultiple sclerosisMedDRA version: 20.0Level: SOCClassification code: 10029205Term: Nervous system disorders Class: 8MedDRA version: 20.1Level: LLTClassification code: 10039720Term: Sclerosis multiple Class: 10029205MedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852CTIS2023-507874-42-00Assistance Publique Hopitaux De Paris80
招募中
1 期
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.multiple myeloma2024-515219-23-00Centre Hospitalier Universitaire De Nantes35
尚未招募
2 期
Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple SclerosisRemitting Relapsing Multiple SclerosisMultiple SclerosisNCT06330077Assistance Publique - Hôpitaux de Paris60
招募中
4 期
Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)2024-514892-16-00REPHA GmbH Biologische Arzneimittel268
招募中
3 期
A study to learn if Rozanolixizumab works and is safe over a long period in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)2023-509237-39-00UCB Biopharma45